Suppr超能文献

门诊囊性纤维化肺部加重期管理中口服抗菌药物的应用:单中心经验

Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.

作者信息

Briggs Elissa Charlotte, Nguyen Thuan, Wall Michael Abraham, MacDonald Kelvin David

机构信息

Oregon Health and Sciences University, Portland, OR, USA.

出版信息

Clin Respir J. 2012 Jan;6(1):56-64. doi: 10.1111/j.1752-699X.2011.00246.x. Epub 2011 Aug 9.

Abstract

INTRODUCTION

Cystic fibrosis (CF) pulmonary disease is characterized by intermittent episodes of acute lung symptoms known as 'pulmonary exacerbations'. While exacerbations are classically treated with parenteral antimicrobials, oral antibiotics are often used in 'mild' cases.

OBJECTIVES

We determined how often management progressed to intravenous (IV) therapy. We also examined multiple courses of oral antimicrobials within one exacerbation, and identified patient factors associated with unsuccessful treatment.

METHODS

We performed a retrospective chart audit of oral antibiotic use in CF patients, from March 2009 through March 2010, for 'mild' CF exacerbations.

RESULTS

Administration of a single vs multiple courses of oral antibiotics for treatment of 'mild' CF exacerbation avoided progression to IV therapy 79.8% and 50.0% of the time, respectively. Overall, oral antibiotics circumvented the need for IV therapy 73.8% of the time. Using multi-variant analysis, we found multiple patient characteristics to be independent risk factors for oral antibiotic failure including a history of pseudomonas infection [odds ratio (OR) 2.13, confidence interval (CI) 1.29-3.54], CF-related diabetes (OR 1.85, CI 1.00-3.41), allergic Bronchopulmonary aspergillosis (OR 3.81, CI 1.38-10.56), low socioeconomic status (OR 1.67, CI 1.04-2.67), and calculated baseline forced expiratory volume in 1 s (FEV1) < 75% of predicted prior to an acute exacerbation (OR 1.93, CI 1.20-3.08). Decline in FEV1 > 10%, weight for age, body mass index, distance from the CF center and gender were not significant.

CONCLUSION

Our observations suggest that one course of oral antimicrobials is frequently effective in outpatient CF pulmonary exacerbations but exacerbations requiring more than one course of oral antibiotics are likely to require IV therapy.

摘要

引言

囊性纤维化(CF)肺部疾病的特征是出现被称为“肺部加重期”的急性肺部症状的间歇性发作。虽然传统上肺部加重期采用胃肠外抗菌药物治疗,但在“轻度”病例中常使用口服抗生素。

目的

我们确定了治疗进展为静脉(IV)治疗的频率。我们还研究了在一次加重期内多次使用口服抗菌药物的情况,并确定了与治疗失败相关的患者因素。

方法

我们对2009年3月至2010年3月期间CF患者因“轻度”CF加重期使用口服抗生素的情况进行了回顾性病历审核。

结果

对于“轻度”CF加重期,使用单疗程与多疗程口服抗生素治疗分别有79.8%和50.0%的时间避免了进展为IV治疗。总体而言,口服抗生素有73.8%的时间避免了IV治疗的需要。通过多变量分析,我们发现多种患者特征是口服抗生素治疗失败的独立危险因素,包括假单胞菌感染史[比值比(OR)2.13,置信区间(CI)1.29 - 3.54]、CF相关糖尿病(OR 1.85,CI 1.00 - 3.41)、变应性支气管肺曲霉病(OR 3.81,CI 1.38 - 10.56)、社会经济地位低(OR 1.67,CI 1.04 - 2.67)以及在急性加重期前计算的基线第1秒用力呼气量(FEV1)<预测值的75%(OR 1.93,CI 1.20 - 3.08)。FEV1下降>10%、年龄别体重、体重指数、距CF中心的距离和性别无显著意义。

结论

我们的观察结果表明,一个疗程的口服抗菌药物在门诊CF肺部加重期通常有效,但需要多个疗程口服抗生素治疗的加重期可能需要IV治疗。

相似文献

1
Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.
Clin Respir J. 2012 Jan;6(1):56-64. doi: 10.1111/j.1752-699X.2011.00246.x. Epub 2011 Aug 9.
6
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Pediatr Pulmonol. 2013 Jul;48(7):666-73. doi: 10.1002/ppul.22652. Epub 2012 Aug 8.
7
Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1137-43. doi: 10.1164/rccm.201001-0057OC. Epub 2010 Jun 25.
10
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatr Pulmonol. 2010 Feb;45(2):127-34. doi: 10.1002/ppul.21117.

引用本文的文献

1
The effect of modulators on lung function following inpatient treatment for CF exacerbations.
Front Pediatr. 2025 Aug 21;13:1654122. doi: 10.3389/fped.2025.1654122. eCollection 2025.
2
3
Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.
Antibiotics (Basel). 2021 Apr 23;10(5):486. doi: 10.3390/antibiotics10050486.
5
Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape.
Chest. 2021 Jan;159(1):93-102. doi: 10.1016/j.chest.2020.09.084. Epub 2020 Sep 20.
7
Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
J Cyst Fibros. 2018 Nov;17(6):760-768. doi: 10.1016/j.jcf.2018.05.015. Epub 2018 Jun 18.
9
Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice.
Br J Pharmacol. 2017 May;174(9):836-847. doi: 10.1111/bph.13741. Epub 2017 Mar 9.
10
One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.
Clin Med Insights Pediatr. 2016 Jul 12;10:57-65. doi: 10.4137/CMPed.S38336. eCollection 2016.

本文引用的文献

1
Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
Pediatr Pulmonol. 2011 Apr;46(4):393-400. doi: 10.1002/ppul.21374. Epub 2010 Oct 21.
3
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32. doi: 10.1164/rccm.200909-1421OC. Epub 2010 May 12.
4
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatr Pulmonol. 2010 Feb;45(2):127-34. doi: 10.1002/ppul.21117.
5
Improving care at cystic fibrosis centers through quality improvement.
Semin Respir Crit Care Med. 2009 Oct;30(5):547-58. doi: 10.1055/s-0029-1238913. Epub 2009 Sep 16.
6
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3.
7
Allergic bronchopulmonary aspergillosis.
Chest. 2009 Mar;135(3):805-826. doi: 10.1378/chest.08-2586.
8
Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.
Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21. doi: 10.1164/rccm.200802-327OC. Epub 2008 Jul 31.
9
Oral anti-pseudomonal antibiotics for cystic fibrosis.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD005405. doi: 10.1002/14651858.CD005405.pub2.
10
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.
Thorax. 2007 Apr;62(4):360-7. doi: 10.1136/thx.2006.060889.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验